Focus: Anteris Technologies is a medical device company specializing in implantable bioscaffolds for cardiovascular applications, headquartered in Australia with a focused pipeline of transcatheter and surgical valve technologies.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Growing — net +13 jobs in 30d
28 jobs added vs 15 removed. Steady team buildout.
Best suited for early-stage device engineers and regulatory professionals seeking specialized cardiovascular experience; financial and pipeline clarity needed before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Lead transcatheter aortic valve replacement program with 4 active trials indicating advanced clinical development.
Help build intelligence for Anteris Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Anteris Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Implantable bioscaffold therapy addressing valve stenosis with 1 active trial.
Advanced 3D adaptive valve program with 1 active trial supporting product differentiation.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles